Plasma parathyroid hormone and risk of congestive heart failure in the community.

Cation dyshomeostasis and cardiomyocyte necrosis: the Fleckenstein hypothesis revisited. Eur Heart J (2011) 0.96

Serum parathyroid hormone and 25-hydroxyvitamin D concentrations and risk of incident heart failure: the Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc (2014) 0.95

Relation of vitamin D and parathyroid hormone to cardiac biomarkers and to left ventricular mass (from the Cardiovascular Health Study). Am J Cardiol (2012) 0.94

Increased Prevalence and Severity of Coronary Artery Calcification in Patients with Chronic Kidney Disease Stage III and IV. Nephron Extra (2012) 0.91

A novel multi-tissue RNA diagnostic of healthy ageing relates to cognitive health status. Genome Biol (2015) 0.90

Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional links. Clin Interv Aging (2013) 0.89

Coronary artery calcification in chronic kidney disease: An update. World J Cardiol (2014) 0.88

Hypertension, Antihypertensive Medications, and Risk of Incident Primary Hyperparathyroidism. J Clin Endocrinol Metab (2015) 0.81

Normocalcaemic, vitamin D-sufficient hyperparathyroidism - high prevalence and low morbidity in the general population: A long-term follow-up study, the WHO MONICA project, Gothenburg, Sweden. Clin Endocrinol (Oxf) (2015) 0.81

Serum 25-hydroxyvitamin D and parathyroid hormone in relation to plasma B-type natriuretic peptide: the Hoorn Study. Endocr Connect (2012) 0.79

Disturbances in calcium metabolism and cardiomyocyte necrosis: the role of calcitropic hormones. Prog Cardiovasc Dis (2012) 0.79

Variability of biomarkers in patients with chronic heart failure and healthy controls. Eur J Heart Fail (2016) 0.79

Intracellular calcium overloading and oxidative stress in cardiomyocyte necrosis via a mitochondriocentric signal-transducer-effector pathway. Exp Clin Cardiol (2011) 0.78

Mineralocorticoid receptor antagonism confers cardioprotection in heart failure. Curr Heart Fail Rep (2013) 0.76

Can parathyroid hormone be used as a biomarker for heart failure? Heart Fail Rev (2013) 0.76

Arterial structure and function in mild primary hyperparathyroidism is not directly related to parathyroid hormone, calcium, or vitamin D. PLoS One (2012) 0.76

Zinc and the prooxidant heart failure phenotype. J Cardiovasc Pharmacol (2014) 0.75

Parathyroid hormone and risk of heart failure in the general population: A meta-analysis of prospective studies. Medicine (Baltimore) (2016) 0.75

Relationship between bone turnover and left ventricular function in primary hyperparathyroidism: The EPATH trial. PLoS One (2017) 0.75

Association of serum parathyrine and calcium levels with primary aldosteronism: a meta-analysis. Int J Clin Exp Med (2015) 0.75

Bone Mineral Density and Risk of Heart Failure in Older Adults: The Cardiovascular Health Study. J Am Heart Assoc (2017) 0.75

Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21

Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08

Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01

Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03

New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89

Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10

Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72

Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2015) 7.99

Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94

Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59

Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med (2008) 7.33

Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest (2009) 7.09

Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66

Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med (2011) 6.44

C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39

Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet (2014) 6.23

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet (2015) 6.13

K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science (2011) 5.40

Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet (2007) 5.21

Genomic inflation factors under polygenic inheritance. Eur J Hum Genet (2011) 4.89

Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation (2009) 4.78

Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet (2012) 4.73

GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science (2013) 4.71

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63

A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37

Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet (2012) 4.16

Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13

Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91

Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA (2011) 3.90

A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older: a randomized controlled trial. Arch Intern Med (2009) 3.83

Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med (2014) 3.81

Insulin resistance and risk of congestive heart failure. JAMA (2005) 3.79

Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet (2010) 3.37

Serum retinol levels and the risk of fracture. N Engl J Med (2003) 3.29

Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25

Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25

Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20

Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA (2012) 3.10

Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ (2006) 3.05

Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ (2007) 2.93

Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92

Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90

Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension (2013) 2.89

Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med (2005) 2.89

Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation (2009) 2.85

Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study. Hypertension (2008) 2.83

Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS Genet (2013) 2.83

New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J (2013) 2.81

Total mortality after changes in leisure time physical activity in 50 year old men: 35 year follow-up of population based cohort. BMJ (2009) 2.79

FTO genotype is associated with phenotypic variability of body mass index. Nature (2012) 2.77

Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. Hypertension (2012) 2.75

Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis (2009) 2.73

Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat Genet (2011) 2.73

Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med (2013) 2.73

Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis (2009) 2.70

CUBN is a gene locus for albuminuria. J Am Soc Nephrol (2011) 2.70

Cardiovascular diseases and risk of hip fracture. JAMA (2009) 2.69

Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension (2010) 2.64

Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int (2012) 2.61